Skip to content

Use of Copeptin in Diabetes Insipidus

Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01940614
Enrollment
156
Registered
2013-09-12
Start date
2013-07-31
Completion date
2017-12-31
Last updated
2018-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Insipidus, Primary Polydipsia

Keywords

Copeptin, differential diagnosis of polyuria polydipsia syndrome, diabetes insipidus, compulsive water drinking, water deprivation test, Diabetes insipidus (central and nephrogenic)

Brief summary

Prospective evaluation of the novel biomarker copeptin in the differential diagnosis of diabetes insipidus against the standard diagnostic test methods.

Detailed description

Purpose of this study is to compare the overall diagnostic accuracy of the three following diagnostic test procedures in diabetes insipidus (central, nephrogenic) and primary polydipsia: a) classical water deprivation test alone, b) classical water deprivation test plus plasma copeptin cut-off levels, c) hypertonic saline infusion test plus plasma copeptin measurement. The investigators hypothesize that firstly b) and c) is better as a). Secondly the investigators hypothesize that c) is non-inferior to b).

Interventions

OTHERWater deprivation test

Classical water deprivation test alone

hypertonic saline infusion test plus plasma copeptin measurement

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Polyuria or/and Polydipsia or/and therapy with synthetic adenovirus proteinase (AVP) derivate * Urine osmolality \<800mOsm/kgH20

Exclusion criteria

* Polyuria due to diabetes mellitus * Hypokalemia * Hyperkalemia (\>5mmol/l) * Hypercalcemia * Kidney disease (min.: glomerular filtration rate (GFR) 60ml/min/1.73m2) * Pregnancy * Hyponatremia \>135mmol/L * Hypernatremia \>145mmol/L * Hypo- or hypervolemia * uncorrected adrenal or thyroidal deficiency * Cardia failure * Epilepsia * Uncontrolled hypertension

Design outcomes

Primary

MeasureTime frameDescription
Overall diagnostic accuracybeginning and end of protocol, up to 9hoursRatio of the number of correctly diagnosed patients to the number of all tested patients for the tests: * classical water deprivation test alone * classical water deprivation test plus plasma copeptin cut-off levels * hypertonic saline Infusion test plus plasma copeptin measurements

Secondary

MeasureTime frameDescription
Sensitivity, specificity, positive and negative predictive valuebeginning and end of protocol, up to 9hourseach diagnostic test
post-hoc best copeptin cut-off optimising overall performancebeginning and end of protocol, up to 9hoursbest copeptin cut-offs for differentiation between different diagnosis of polyuria-polydipsia syndrome
subjective burden as rated by patients on visual analogue scalebeginning, during and end of protocol, up to 9hourswater deprivation test and hypertonic saline Infusion test
Predictive value of specific anamnestic and clinical featuresbefore testsEvaluation of anamnestic and clinical features to test-independently predict final diagnosis of polyuria-polydipsia syndrome
Predictive value of absent bright spot in posterior pituitary enlargementbefore or after testsEvaluation of predictive value of absent bright spot in T1 weighted cranial MRI scans

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026